Skip to main content

Table 4 Tumor characteristics at diagnosis according to pathological complete response

From: Mammographic density is a potential predictive marker of pathological response after neoadjuvant chemotherapy in breast cancer

  

pCRa

Non-pCR

Number of patients

 

57

245

Estrogen receptor status

positive

18 (31.6)

165 (67.3)

negative

38 (66.7)

72 (29.4)

missing

1 (1.8)

8 (3.3)

Progesterone receptor status

positive

12 (21.1)

128 (52.2)

negative

44 (77.2)

109 (44.5)

missing

1 (1.8)

8 (3.3)

HER2 status

positive

35 (61.4)

60 (24.5)

negative

20 (35.1)

171 (69.8)

missing

2 (3.5)

14 (5.7)

Ki67

> 20% (high)

44 (77.2)

161 (65.7)

<=20% (low)

3 (5.3)

36 (14.7)

missing

10 (17.5)

48 (19.6)

Axillary lymph node

positive FNAb

41 (71.9)

156 (63.7)

negative FNA

3 (5.3)

19 (7.8)

inconclusive FNA

 

5 (2.0)

no FNA

13 (22.8)

64 (26.1)

missing

 

1 (0.4)

Tumor size at diagnosis (mm)c

median (IQR)

28 (20–35)

35 (25–46)

  1. apathological complete response
  2. bfine needle aspiration
  3. cMeasured in mammograms or in ultrasound images. When both methods were conclusive an average measure was used